61 results about "PCSK9 Inhibitors" patented technology

The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.

Treatment of severe hyperlipidemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof in combination with a PCSK9 inhibitor.

The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.

The invention relates to an application of a PCSK9 inhibitor in malignant tumor immunotherapy. The PCSK9 inhibitor can effectively inhibit tumour. Through increasing of expression of an immunocyte activation related gene, the immunocyte activity can be enhanced by the PCSK9 inhibitor, and the tumour can be inhibited. The invention also reveals obvious effect of combined application of the PCSK9 inhibitor and a PD-1 inhibitor for increasing immunocyte activity and tumour inhibition.

The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and established CHD or CHD risk equivalents that are not adequately controlled by maximum tolerated dose statin therapy.

The invention belongs to the technical field of medicine biologics, relates to functions and mechanisms of PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) in treating T-cell medicated inflammatory-immune diseases, application of a PCSK9 inhibitor in preparing a medicine for treating T-cell medicated inflammatory-immune diseases, and in particular relates to application of a PCSK9 small-molecule interference RNA or PCSK9 small-molecule inhibitor in preparing medicines for preparation systems or external skin application in treating psoriasis, atopic dermatitis or urticaria. Psoriasis is adopted as a testing bed for inflammatory-immune disease research, results show that the PCSK9 small-molecule inhibitor or small-molecule interference RNA has treatment effects which are remarkably prior tothose of PCSK9 monoclonal antibodies in treating inflammation such as psoriasis. The PCSK9 small-molecule interference RNA or PCSK9 small-molecule inhibitor can be further developed into novel medicines for treating inflammatory-immune diseases such as psoriasis, and is small in side effect, low in cost and remarkable in treatment effect.

The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.

Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.

The present invention discloses a lipid nanoparticle comprising a lipopeptide molecule, dioleoyl phosphoethanolamine, cholesterol, and polyethylene glycol, and the lipid nanoparticle encapsulates Cas9mRNA and a sgRNA molecule in a gene conserved region of target mouse and human Proprotein Convertase subtilisin/kexin type 9 ( PCSK9). The present invention also discloses a preparation method and use of the lipid nanoparticle, and a pharmaceutical composition and formulation comprising the lipid nanoparticle. The lipid nanoparticle and the biological preparation can be used as a novel delivery system for a PCSK9 inhibitor hypolipidemic drug.

The present invention relates to PCSK9 inhibitors and methods of use thereof. Specifically, the invention relates to PCSK9 cell-based assay, PCSK9 inhibiting polypeptides and derivatives thereof. The invention includes pharmaceutical compositions comprising a PCSK9 inhibitor polypeptide together with a pharmaceutically acceptable carrier and method for treating cardiovascular disorders, inflammatory diseases or inflammatory response to infection.

A method for inhibiting ectopic calcification of bodily organs caused by elevated LDL cholesterol is provided. The method includes administering an LDL lowering agent to a patient, comprising a PCSK9 inhibitor selected from Evolocumab, Alirocumab, Praluent, Repatha Pushtonix, Repatha autoinjector, and combinations of the foregoing.

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.